Assuntos
Quimiocina CCL17/sangue , Ciclosporina/uso terapêutico , Dermatite Atópica/tratamento farmacológico , Antígeno Ki-1/sangue , Ácido Micofenólico/uso terapêutico , Biomarcadores/sangue , Quimiocina CCL17/análise , Dermatite Atópica/sangue , Dermatite Atópica/diagnóstico , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Humanos , Antígeno Ki-1/análise , Masculino , Variações Dependentes do Observador , Projetos Piloto , Prognóstico , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Método Simples-Cego , Comprimidos com Revestimento Entérico , Resultado do TratamentoRESUMO
BACKGROUND: The purpose of this study was to determine the utility of post-transplant serum soluble CD30 levels as a biomarker for the development of the bronchiolitis obliterans syndrome (BOS) after lung transplantation during a tacrolimus/mycophenolate mofetil-based regimen. METHODS: Soluble CD30 (sCD30) concentrations were measured prior to transplantation and in 175 samples taken after transplantation in 7 patients developing BOS and 7 non-BOS patients closely matched for age, underlying diseases, follow-up and gender. RESULTS: High pre-transplant sCD30 levels dropped significantly after lung transplantation, but in the post-transplant samples no differences could be detected between patients developing BOS or not, and no changes were found prior to or during the development of BOS. CONCLUSIONS: After transplantation, sCD30 levels are consistently suppressed, but BOS is not prevented, indicating that sCD30 cannot be used as a biomarker to predict BOS after transplantation in the regimen employed.